Abstract | OBJECTIVE: METHODS: RESULTS: The response rate of the study group and the control group was 94% and 67% in SCLC (P > 0.05), 12% and 22% in NSCLC (P > 0.05) and 71.4% and 67% in BC (P > 0.05), respectively. The major side effects were myelosuppression and gastrointestinal reactions, the frequency and intensity of which were statistically not different in the 2 groups of patients. CONCLUSION:
|
Authors | Q Li, J Zhou, F Qu |
Journal | Zhonghua zhong liu za zhi [Chinese journal of oncology]
(Zhonghua Zhong Liu Za Zhi)
Vol. 23
Issue 2
Pg. 170-2
(Mar 2001)
ISSN: 0253-3766 [Print] China |
PMID | 11783029
(Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Powders
- Solutions
- Carboplatin
|
Topics |
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Carboplatin
(adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Carcinoma, Small Cell
(drug therapy, pathology)
- Gastrointestinal Diseases
(chemically induced)
- Humans
- Leukopoiesis
(drug effects)
- Lung Neoplasms
(drug therapy, pathology)
- Neoplasms
(drug therapy, pathology)
- Powders
- Solutions
- Treatment Outcome
|